Overview

A Study of BL-B01D1 + Pembrolizumab Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab bevacizumab) in patients with recurrent or metastatic cervical cancer and endometrial cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab
pembrolizumab